About us
Science
Pipeline
News
Careers
Connect
Legal
Developing
Rapid-Acting Treatments for Neuropsychiatric Diseases
See latest data
Our Focus
TSND-201 (methylone)
a rapid-acting neuroplastogen
for PTSD
We are excited to develop new drugs for the millions of people for whom current psychiatric medicines have not worked.
Learn More
News
The Latest From Transcend
Read More
Media
Fierce Biotech: Psychiatry biotech hopes to Transcend PTSD rivals with new data
Read More
Poster Presentation
TSND-201 (methylone) for PTSD: Initial Results from Open-Label Study (IMPACT-1)
Read More
Press Release
Transcend Therapeutics Announces Positive Open-Label Data from IMPACT-1
Read More
Poster Presentation
Methylone: Distinct Pharmacological and Mechanistic Effects Compared with MDMA
Learn More
Our Mission
Striving for a world without neuropsychiatric disease.
Because 1 billion patients
deserve better.
Careers
Help us bring new mental health solutions to patients
Join us in creating a world free from neuropsychiatric disease.
Learn More